we evaluated the use of the CEPRATE SC stem cell concentrator (CellPro, Inc, Bothell, WA) t o select CD34+ cells from the bone marrow (BM) of 25 patients with non-Hodgkin's lymphoma in complete remission. This system uses the biotinylated 12.8 IgM MoAb t o select CD34+ cells. Cells are retained on an avidin column and detached by agitation. Fifteen patients have been transplanted with the CD34+ purified fraction. The CD34+ purified fraction of the 25 processed BMs contained a median of 0.54% of the original nucleated cells in a volume of 5 t o 10 mL. The median concentration of CD34+ cells was 49% (range, 12% t o 80%). and the median enrichment of CD34+ cells was 33-fold (range, 9-t o 85-fold). This selected CD34+ fraction retained 6096 (range, 15% t o 95%) of late granulocyte-macrophage colony-forming units (CFU-GM), 55% (range, 12% t o 999'0) of early CFU-GM, and 31% (range, 2% t o 100%) erythroid burst-forming units (BFU-E) corresponding t o median enrichments of 22-fold (range, 1-t o 71-fold), 19-fold (range, 2-t o 58-fold), and 14-fold (range, 2-t o 200-fold), respectively. There was a correlation between immune phenotypes and progenitor cells. In the initial buffycoat fractions, the percentage of CD34+ cells was correlated to the cloning efficiency of both late CFU-GM ( P < .05) and early CFU-GM ( P < .001). In the final selected fraction, there was a correlation between the percentage of CD34+/CD33-and the cloning efficiency of early CFU-GM ( P < .05) and between the percentage of CD34+/CD33+ and the cloning efficiency of late CFU-GM ( P < .05L Lymphoma cells positive IGH-DOSE INTENSIFICATION followed by transplantation of autologous bone marrow (ABMT) or peripheral blood stem cells is currently used to consolidate patients with non-Hodgkin's lymphoma (NHL). This approach has been shown to improve prognosis in patients with intermediate-or high-grade NHL when used in chemosensitive relapses'.' or in first remission (CR1).3.4 Similarly, several ongoing studies are investigating the impact of highdose intensification with stem cell rescue in early remission5-' of low-grade lymphoma.
From September 1992 t o January 1994, we evaluated the use of the CEPRATE SC stem cell concentrator (CellPro, Inc, Bothell, WA) t o select CD34+ cells from the bone marrow (BM) of 25 patients with non-Hodgkin's lymphoma in complete remission. This system uses the biotinylated 12.8 IgM MoAb t o select CD34+ cells. Cells are retained on an avidin column and detached by agitation. Fifteen patients have been transplanted with the CD34+ purified fraction. The CD34+ purified fraction of the 25 processed BMs contained a median of 0.54% of the original nucleated cells in a volume of 5 t o 10 mL. The median concentration of CD34+ cells was 49% (range, 12% t o 80%). and the median enrichment of CD34+ cells was 33-fold (range, 9-t o 85-fold). This selected CD34+ fraction retained 6096 (range, 15% t o 95%) of late granulocyte-macrophage colony-forming units (CFU-GM), 55% (range, 12% t o 999'0) of early CFU-GM, and 31% (range, 2% t o 100%) erythroid burst-forming units (BFU-E) corresponding t o median enrichments of 22-fold (range, 1-t o 71-fold), 19-fold (range, 2-t o 58-fold), and 14-fold (range, 2-t o 200-fold), respectively. There was a correlation between immune phenotypes and progenitor cells. In the initial buffycoat fractions, the percentage of CD34+ cells was correlated to the cloning efficiency of both late CFU-GM ( P < .05) and early CFU-GM ( P < .001). In the final selected fraction, there was a correlation between the percentage of CD34+/CD33-and the cloning efficiency of early CFU-GM ( P < .05) and between the percentage of CD34+/CD33+ and the cloning efficiency of late CFU-GM ( P < .05L Lymphoma cells positive IGH-DOSE INTENSIFICATION followed by transplantation of autologous bone marrow (ABMT) or peripheral blood stem cells is currently used to consolidate patients with non-Hodgkin's lymphoma (NHL). This approach has been shown to improve prognosis in patients with intermediate-or high-grade NHL when used in chemosensitive relapses'.' or in first remission (CR1).3.4 Similarly, several ongoing studies are investigating the impact of highdose intensification with stem cell rescue in early remission5-' of low-grade lymphoma.
In all instances, infusion of stem cells to NHL patients bears the intrinsic risk of also infusing tumor cells, even when tumor contamination of the graft has not been detected by histology. The traceable translocation t(14; 18) has been detected by polymerase chain reaction (PCR) in BM and/or blood of more than 75% of the patients with low-grade follicular lymphomas."" This includes patients with localized disease (stage I and 11) at presentation" and patients in complete remission (CR) after conventional chemotherapy." Effective purging of the BM autograft has been shown to be correlated with a lower relapse rate." Current methods of purging lymphoma cells in NHL have consisted of lysis by monoclonal antibodies (MoAbs) with complement2 or incubation with a cyclophosphamide derivative, mafosfamide.'3"4 These techniques are cumbersome and potentially harmful to normal progenitors. Recent studies have shown that BM progenitor cells that bear the CD34 antigen can be isolated and concentrated by a biotin-avidin immunoadsorption for t(14;18) were found by polymerase chain reaction in 9 of 14 buffy coats tested before CD34+ cell purification. In 8 cases, the CD34+-selected fraction was found t o be negative, and the CD34-fraction was found t o be positive. After cryopreservation, the recoveries of progenitor cells in the CD34+-purified fraction were 79% for late CFU-GM, 7196 for early CFU-GM, and 73% for BFU-E. The 15 patients transplanted with the concentrated CD34+ fraction received a median dose of 1 x 10' CD34+ cells/kg (range, 0.3 t o 2.96) and 10.62 respectively. The median numbers of red blood cell (RBC) units transfused was 8 (range, 4 t o 191. The median number of platelet transfusions was 8 (range, 3 t o 31). Neutrophil recovery was quicker in patients receiving the higher doses of BFU-E ( P = .05); these patients also received fewer platelet transfusions ( P = .04). One patient remains thrombocytopenic and platelet-dependent 6 months posttransplant. This patient received the lowest dose of CD34' cells (0.3 x 10'1 kg). This suggests, as a general guideline, t o avoid transplanting patients with doses of BM CD34+ cells below 0.5 x 10'/kg. Of the 15 patients transplanted, l 1 are presently alive in complete remission from 2 t o 17 months posttransplant. This study provides further evidence that CD34+ stem cell concentrates can be used t o reconstitute hemopoiesis and decrease the tumor contamination of the graft. method and are able to reconstitute hemopoiesis in anim a l~'~"~ and patients with neuroblastoma or breast ~ancer.'"'~ Because lymphoma tumor cells do not bear the CD34 antigen," positive selection can be proposed to NHL patients with several potential benefits including a reduction in the tumor contamination of the graft. Here, we report on the preparation of CD34+ stem cell concentrates and the engraftment data as the conclusion of a phase-l to -2 trial.
MATERIALS AND METHODS
From September 1992 to January 1994, purified CD34+ fractions were prepared from the BM of 25 patients with NHL, harvested in preparation for ABMT. Fifteen patients have been transplanted. BM harvested, CD34 concerttrution, und cryopreservution. Under general anesthesia, BM was harvested in heparinized flask (heparin, 100 IU/mL; Roche, NevillylSeine, France) from the posterior iliac crests. In all patients, 0.5 X 10' nucleated cells/kg was stored unprocessed to serve as a back-up. A buffy coat was obtained from the second part by centrifugation using a COBE 2991 blood cell processor (COBE Laboratories, Lakewood, CO) at 3,000 rpm for I O minutes. The product was washed twice with 1,000 mL of phosphatebuffered saline (PBS; Dulbecco's without Ca" and Mg"; GIBCO, Paisley, Scotland) and concentrated in a 150-mL final volume of PBS with 0.1% human serum albumin (HSA). The cell suspension containing a median of 2 X 10" cells ( I X 10"' to 5.2 X 10"') was then incubated with 20 p g / m L of the biotinylated 12.8 MoAb'" for 25 minutes at room temperature. After washing with PBS to remove any antibody excess, this antibody-sensitized buffy-coat fraction was filtered through the Ceprate avidin column (Ceprate Stem Cell Concentrator; CellPro, Bothell, WA).
In this system, the CD34' cells link to the avidin-coated polyacrylamide beads through an G 'avidinbiotin-anti-CD34 antibody-CD34+ cell" complex. After washing the column with 300 mL of PBS-HSA 1% to remove nonspecitically bound cells, the CD34' cells were released from the avidin beads by mechanical agitation and recovered with 90 mL of PBS-HSA I % supplemented with 10 IU/mL heparin. Aliquots were taken from both CD34-and CD34+ fractions for flow cytometric analysis and progenitor cell culture assays. The selected CD34' suspension was centrifuged for IO minutes at 500g and resuspended in 4.5-mL aliquots of PBS medium (GIBCO) with 7.5% dimethylsulfoxide and 4% HSA. This suspension was then cryopreserved in liquid nitrogen using controlled-rate freezing and stored at -196°C2' to be reinfused later into the patient.
F/ow cyrornetric. mal-ysis. The initial buffy-coat and CD34' fractions were analyzed on a flow cytometer (FACSort; Becton Dickinson, Lincoln Park, NJ). Double labeling was used in the CD34'-selected fraction to evaluate the following phenotypes: CD34/CD33, CD34/CD38, CD34/HLA DR, CD34/CD19, and CD34/CD2. Because of the low concentration of this specific cell population, the initial buffy coat could be reliably analyzed only for the percentage of CD34' cells. A half-million buffy-coat cells and 10' CD34'-selected cells were incubated with I O p L fluorescein-and phycoerythrin-labeled antibodies in 100 pL PBS for 20 minutes at 4°C. After two washes with PBS l % bovine serum albumin (BSA), the cells were fixed with 500 /IL of PBS 1% paraformaldehyde solution. To define the exact percentage of CD34' cells in the two fractions, we compared the dot-plot of side scatter and fluorochrome green or red with the double-labeled negative control and with the cell control.
A total of I X IO4 to 2 X 1 6 cells were analyzed . We analyzed the cell phenotypes in the selected fraction as follows: CD34'/CD33-. CD34+/HLA DR-, CD34'/CD38-for early progenitor cells; and CD34+/CD33' for late progenitor cells.
Hernatopoi'etic culture ussays. We used two types of culture assays to quantitate late and early progenitors as described below.
The assay for early granulocyte-macrophage colony-forming units (CFU-GM) and erythroid burst-forming units (BFU-E) was performed according to the technique of Eaves and Eaves." Briefly, S x I O 4 mononuclear cells (MNCs) were plated in 35-mm petri dishes in I-mL aliquots of lscove's modified Dulbecco's medium containing 30% fetal calf serum (GIBCO), 10 mg/mL detoxified BSA (Sigma, St Louis, MO), and 0.92% methylcellulose (Flucka, Buchs. Switzerland). Cultures were stimulated with a mixture of human recombinant growth factors: interleukin-3 (10 ng/mL; Sandoz, Basel. Switzerland). granulocyte colony-stimulating factor (G-CSF; I0 ng/ mL; Amgen, Thousand Oaks, CA), granulocyte-macrophage CSF (GM-CSF; 10 ng/mL; Schering-Plough, Kenilworth, NJ), erythropoietin (3 U/rnL; Boehringer, Mannheim, Germany), and stem cell factor (SCF; l00 ng/mL; Immunex, Seattle, WA). Dishes were incubated at 37°C in a humidified 5% CO2 atmosphere. Three dishes were plated for each culture. Granulocyte-macrophage colonies (CFU-GM; more than 50 cells) and erythroblastic colonies (BFU-E) were scored on day 14.
The assay for late CFU-GM was performed in agar according to the technique of Pike and Robinson.2' The basic medium was McCoy's SA medium without serum (GIBCO-Biocult, Paisley, Scotland) supplemented with 30% heat-inactivated fetal calf serum. Colony-stimulating activity was supplied by 10% human placentaconditioned medium. Buffy-coat and concentrated CD34' cells were seeded at 5 X 10'/mL and IO'/mL, respectively, of medium containing equal volumes of 0.6% agar and 2X McCoy's SA medium to achieve a final serum concentration of 15%. Three 35-xI0-mm petri dishes (Greuner, Frickenhausen, Germany) were plated for each assay. The cultures were incubated for 10 days at 37°C in a humiditied 5% CO2 atmosphere. The CFU-GM were scored on day IO.
Detection of residual disease. Bcl-2 rearrangement at the major breakpoint region (MBR) was performed according to a slightly modified technique described by Gribben et al.'" Briefly, DNA was extracted using a standard procedure, heated to 96°C for 10 minutes to destroy proteinase-K activity. Each sample was amplified by PCR using nested oligonucleotide primers as follows. PCR was performed in a 50-p,L final volume using 1.5 p g of DNA; 200 nmol/L oligonucleotide primers; 200 mmol/L each of deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate, and deoxytyrosine triphosphate; 1.5 U Taq polymerase (Cetus, Emeryville, CA) in PCR buffer (SO mmol/L KCL, 10 mmol/L Tris-Cl. 2.25 mmol/L Mg Cl,, 0.01% BSA). The initial amplification was performed for 25 cycles in a Perkin Elmer-Cetus (Norwalk, CT) thermal cycler with the oligonucleotides S'-CAGCCTTGAAACATT-GATGG-3' for the MBR and 5'-ACCTGAGGAGACGGTGACC-3' for the JH consensus region. Each cycle was performed with 1 minute of denaturation at 94"C, 1 minute of annealing at 56°C for the MBR amplification, and I minute of extension at 72°C. The tinal extension period was extended to 10 minutes.
Reamplification of a 5-pL aliquot of this amplified mixture was performed for 30 cycles using oligonucleotide primers internal to the original primers, S'-TATGGTGGT'TTGACCTTTAG-3' for the MBR and S'-ACCAGGGTCCCTTGCCCCA-3' for the J, consensus region with I minute of denaturation at 94°C I minute of annealing at 5X"C, and 1 minute of extension at 72°C. The final extension period was again extended to 10 minutes. Aliquols of this tinal reaction were analyzed by electrophoresis and visualized by staining with ethidium bromide under UV light. Then, the reamplified DNA was blotted by alkaline transfer onto Hybond N' membranes (Amersham, Buckinghamshire, UK) and bcl-2-specific DNA was detected by hybridization overnight with 32P-labeled oligonucleotide probes, S'CCCTCCTGCCCTCCTTCCG-3' for the MBR. Oligonucleotides were radiolabeled with (y'*P) adenosine triphosphate using T4 polynucleotide kinase (Boehringer) according to the manufacturer's instructions.
A positive control consisting of DNA from RL cells, a lymphoma cell line with a t( 14; 18) translocation, and a negative control consisting of the PCR buffer with heat-inactivated proteinase K was included in each experiment. Each sample was analyzed at least twice. The limit of sensitivity of the technique, optimized by using Table 5 . The median age of the population was 45 years (range, 31 to 57 years), and the sex ratio (W) was 1.5. A total of 11 patients had follicular lymphoma including 1 in transformation, 2 had intermediate-grade, and 2 high-grade lymphoma, including 1 CD30 (Ki1)-positive T-cell lymphoma. At initial diagnosis, 2 patients were stage MI, and 13 were stage IIIlIV with detected BM infiltration by biopsy in 7 of them, all low-grade (64% of all follicular lymphomas). At time of BM harvesting, no patient had tumor BM infiltration detected on pathologic examination of BM aspiration and biopsy. The pretransplant intensification regimen was BEAM consisting of 300 mg/ m' BCNU on day -7, 200 mg/m' etoposide intravenously, and 200 mg/m' cytosine-arabinoside by continuous infusion from day -6 to day -3, and 140 mg/m2 high-dose melphalan intravenously on day -2. The frozen CD34+ fraction was rapidly thawed, diluted in 
RESULTS
In vitro studies. BM samples obtained from 25 patients with NHL were processed to yield a CD34+ stem cell concentrate. Results of cell phenotype analysis and culture assays are reported in Table 1 .
In the initial buffy coat, the concentration in CD34+ cells varied from 0.44% to 7.2%, with a median value of 0.9%. The median number of progenitor cells in cultures expressed per lo5 MNCs plated were 122 for late CFU-GM, 267 for early CFU-GM, and 172 for BFU-E. In the CD34+-selected fraction, the median concentration of CD34+ cells was 49%, with a range of 12% to 80%. The enrichment in CD34' cells was 33-fold (range, 9-to 85-fold). Analysis of subpopulations indicated that the CD34+ population was a mixture The values are given as the median with the range in parentheses.
t N = 25. Early CFU-GM and BFU-E were grown on methylcellulose with addition of 5 cytokines (stem cell factor, interleukin-3, G-CSF, GM-CSF, erythropoietin); late CFU-GM were grown on agar with placenta-conditioned medium.
* N = 25.
of immature (CD34+/CD33-; 17%) and mature progenitors (CD34+/CD33+; 21.5%) with very few putative multipotent progenitors corresponding to the CD34+/HLA DR-or CD34+/CD38-phenotype (0.9% and 1.5%, respectively). Interestingly, lymphoid progenitors corresponding to the CD34+/CD19+ phenotype accounted for a median of 11% of the.overd1 cell population.
The median values for progenitor cells expressed per lo5 MNCs plated in culture were 2,570 for late CFU-GM, 4,762 for early CFU-GM, and 1,900 for BFU-E. Overall, the CD34-selected fraction (recovew) contained a median of 60% (range, 15% to 95%) late CFU-GM, 55% (range, 12% to 99%) early CFU-GM, and 31% (range, 2% to 100%) BFU-E, which corresponds to median enrichments of 22-fold (range, 1-to 71-fold), 19-fold (range, 2-to %-fold), and 14-fold (range, 2-to 200-fold), respectively.
In the initial buffy-coat fractions, there was a correlation between the percentage of CD34+ cells and the cloning efficiency of both late CFU-GM (P < .05) and early CFU-GM (P < .001) progenitors (Fig 1A and B) .
In the selected fraction, the analysis of subsets by phenotypes showed a correlation between the percentage of CD34+/CD33-and the cloning efficiency of early CFU-GM ( P < .05) (Fig 2A) . There was also a correlation between the percentage of CD34+/CD33+ and the cloning efficiency of late CFU-GM (P < .05; Fig 2B) . There was no correlation between the CD34+/CD38-and CD34+/HLA DR-cell populations and the cloning efficiencies of early or late progenitors.
The purity of the selected fraction was higher for initial buffy-coat fractions, with a CD34 concentration above the median 0.9% value (59% v 32%; P < .01). The cryopreservation efficiencies in the purified CD34+ fractions were available for patients that received transplants. Recoveries of early and late CFU-GM and BFU-E after thawing were identical to those obtained with frozen-thawed initial fractions (buffy-coats; see Table 1) .
At a time when tumor contamination was not detected by routine pathologic examination of aspiration and biopsy in any of these patients, lymphoma cells positive for t (14; 18) were found by PCR in 9 (8 patients) of 20 buffy-coats (19 patients, including 14 with follicular NHL) tested before CD34"cell purification. In 8 cases, the CD34+-selected fraction was found to be negative, and the CD34-fraction was found to be positive. Interestingly, this includes 2 BM collections in 1 patient (first collection insufficient for a safe graft by conventional criteria in use in our institution) leading to 2 buffy coats separately processed; the two procedures gave the same results showing twice effective purging. In one case, the CD34' fraction still contained t( 14; 18) tumor cells ( Table 2) .
Clinical data. The number of progenitor cells infused, kinetics of engraftment and blood support for all patients are shown on Table 3 .
All patients engrafted successfully on neutrophils with a median to recovery to 0.5 X 109/L of 15 days (range, 10 to 33). One patient was not evaluable for platelet recovery because he died of tumor progression on day 30. Of the 14 evaluable patients, 13 recovered a platelet count over 50 X 109L at a median of 23 days (range, 11 to 68). One patient is still thrombocytopenic and supported by platelet transfusion at 6 months. This patient received the lowest dose of CD34+ cells (0.3 X 106/kg); this also corresponded to the lowest doses of early C m -G M (0.92 X 104/kg) and BFU-E (0.84 X 104/kg). The median number of transfused RBC units and the median number of platelet transfusions was 8 (range, 4 to 19) and 8 (range, 3 to 31+), respectively, with the two extremes (19 RBC units and 3 1' platelet transfusions) for the patient receiving the lowest doses of CD34'-selected cells. There was a trend for more rapid recovery . , . , . , . , . For personal use only. on October 22, 2017. by guest www.bloodjournal.org From of neutrophils in patients receiving the higher doses of CD34+ cells ( P = . l 1) or early CFU-GM ( P = .lo). Neutrophil engraftment was more rapid in patients receiving the higher doses of BFU-E (P = .05; R = -0.45). These patients also received fewer platelet transfusions ( P = .M). Table 4 indicates the kinetics of recovery of early CFU-GM and BFU-E in BM and peripheral blood.
Of the 15 patients, 11 are presently alive in CR from 2 to 17 months posttransplant. One patient transplanted while his tumor was in relapse died on day 30 posttransplantation from tumor progression. Three patients in CR posttransplant have relapsed at 5, 8, and 10 months (Table 5) .
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DISCUSSION
This study reports results of a phase-I to -11 trial designed to test the feasibility of using CD34+ stem cell ABMT after the administration of a myeloablative regimen for consolidation in patients with NHL.
The role of high-dose consolidation with the BEAM regimen or the combination of cyclophosphamide and total body irradiation has been clearly established in patients with chemosensitive relapse.'.' This protocol is presently being tested in our institution and in others for patients in first remission, regardless of the grade, including patients with low grade (follicular lymph~ma).~-'.'~ The population of patients in the present study included all consecutive NHL patients autografted in our institution in the 16-month period of the trial. Eleven patients had follicular NHL, and four patients had high-or intermediate-grade lymphoma, of whom 3 were beyond CR1 and 1 in CR1, who was included in view of having a very poor prognosis (anaplastic large cell T lymphoma CD30+ with lymph node and cutaneous infiltration). Indeed, this last patient relapsed posttransplant.
Transplantation of concentrated CD34+ stem cells, rather than infusion of autologous BM or leukapheresis products, has the advantage of reducing volume, which facilitates storage and decreases the amount of dimethylsulfoxide and cell lysis products. This decreased volume has been shown to reduce cardiovascular side effects (specifically, maximal heart rate and blood pressure) that are observed with standard BM inf~sion.'~ More importantly, the risk of infusing tumor cells while performing an autograft has led to the development of multiple techniques aimed at the removal or destruction of occult tumor cells that potentially contaminate the graft. The level of toxicity of these methods (referred to as negative selection) toward the normal stem cell compartment ensuring engraftment is variable but potentially high, espe- Several techniques have been developed to concentrate CD34+ stem cells for autografting. All of these techniques rely first on the recognition of these cells through their immunophenotype, CD34' a l~n e *~* *~ or, for instance, CD34+ Thy1+27 or CD34+/CD38-." Afterwards, the selection of cells is performed using panning:5 immunomagnetic beads:6 highly efficient cell sorting:' or the CellPro Ceprate device used in the current study. Considerable in vitro data has been reported on the CD34+ and the CD34-subpopulations obtained with these different approaches. These results indicate that the CD34+ fraction is heterogeneous and contains both mature committed progenitors (CFU-GM, BFU-E), ensuring early recovery from aplasia, and immature progenitors, ensuring long lasting hemopoietic reconstitution. Successful engraftment has been obtained in several animal models, including monkeys, with the CD34' fra~tion""~ but not with the CD34-fraction. In humans, consistent engraftment in a large series of patients has been reported with the biotin-avidin immunoadsorption technique. The simplicity of this technique makes it easy to use in a hematology laboratory. In a comparative study of engraftment kinetics in 44 patients with breast cancer who received ablative chemotherapy followed by infusion of CD34+ concentrates from BM with or without infusion of growth factors, Shpall et a l l s have reported median days to neutrophil recovery to 0.5 X 109L of 23 days with BM alone, of 16 days when adding GM-CSF, and of 10 days when adding G-CSF posttransOur study provides further evidence that CD34' cell concentrates are capable of reconstituting hematopoiesis in patients receiving myeloablative therapy. The study also provides data on several practical aspects regarding the preparation of the concentrates. A first observation was that the purity and recovery of CD34+ cells varied from patient plant. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From to patient. Our results are similar to those observed by others using the CellPro CEPRATE and other techn i q u e~?~ These results are probably related to our observation that the purity of the selected fraction was related to the concentration of CD34+ cells before selection.
The correlation of CD34' cells by immunophenotyping to early and late CFU-GM by culture both in the buffy-coat fraction before selection and in the CD34+ selected cells is consistent with prior studies. Furthermore, the finding in the latter of a linear correlation linking the CD34+/CD33-subset to early CFU-GM and the CD34+/CD33+ subset to late C m -GM is not unexpected. It confirms that the CD34' cell content of the purified fraction, in part, reflects its potential to reconstitute hemopoiesis. When looking at the kinetics of engraftment, patients receiving the lowest doses of CD34' cells tended to engraft more slowly both on neutrophils and platelets. The only patient who had not recovered platelets at 6 months posttransplant received the lowest dose (0.3 X lo6 of CD34+ cellskg), which also translated into the lowest doses in Cm-GM and BFU-E. The absence of a statistically significant correlation between engraftment and the number of CD34+ cells may result from the limited number of patients transplanted. Further transplants with low doses of CD34+ cells would be necessary to establish a safety threshold, which, for ethical reasons, will never be done. Therefore, we have established a general guideline to only transplant patients with doses of BM CD34+ cells above 0.5 X 106kg. This safeguard comes as an addition rather than a replacement of our previously established minimum threshold of lo4 late CFU-GM/kg.
The detection of the bcl-2 translocation in BM buffy coats from 8 of 19 patients (meaning 8 of 14 with follicular lymphoma (57%) and none with concomitant detectable tumor infiltration by conventional cytology and histology) is a confirmation of the high rate of tumor contamination in BM previously reported in patients at all stages of disease, even those in remission, using molecular biologic technique.""' In preclinical experiments, we (R.J.B.) have used normal BM contaminated with tumor cells from either the HSB2 or the DAUDI lymphoma cell lines; by fluorescence microscopy to detect tumor cells, we have been able to show a 3-logarithm reduction in the enriched cell population compared with BM before separation." In the present study, tumor contamination assessable through nested PCR at the level was no longer detected in 8 of the 9 CD34+-purified fractions. In the clinical setting, these results indicate that CD34+ cell purification may reduce signicantly the tumor load of the infused graft. However, further evaluation is needed on larger series of patients.
This phase-l to -2 study did not address the question of the value of early ABMT in NHL or follicular NHL, nor was it designed to assess the value of positive selection of BM in this context. These results do show that CD34' progenitor cell concentrates contain less contamination with tumor cells and retain full engraftment capacity in patients with NHL.
Ongoing laboratory experiments using cell lines show that up to a 4-logarithm reduction in tumor contamination is attainable when using two successive passages on the avidin column after reloading with the anti-CD34 antibody. Further studies are obviously needed to better define high-dose therapy management of follicular lymphomas and to compare it with conventional management.
